LifeCodexx Begins Clinical Validation Study of Sequencing-Based T21 Test
June 29, 2011
LifeCodexx Begins Clinical Validation Study of Sequencing-Based T21 Test
The company will conduct the clinical validation study on 500 samples in conjunction with several European prenatal centers.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Sequencing-Based Fetal Testing Market Heats up as Verinata Plans 2012 Launch for Down Syndrome Dx
May 4, 2011 / Clinical Sequencing News - Sequenom Outlicenses Technology for T21 Test, Returns Rights of Separate Patent to TrovaGene
August 17, 2011 / Clinical Sequencing News - As Rivals Vie for Share of Noninvasive Trisomy Testing Market, Physicians See Value for Screening
July 3, 2012 / Clinical Sequencing News - Quake Group Issued Patent for Detection of Fetal Aneuploidy with Next-Gen Sequencing
August 31, 2011 / Clinical Sequencing News - Sequenom Ramps up Hiring, Licenses Additional Technology as it Nears Launch of T21 Test
August 9, 2011 / Clinical Sequencing News